Exact Sciences launched Cancerguard, a multi-cancer early detection (MCED) blood test designed to identify more than 50 types of cancer by detecting tumor-associated alterations in circulating DNA and proteins. Demonstrating 68% sensitivity across six deadly cancers and 64% overall sensitivity, the test addresses an unmet need for broad cancer screening. Exact Sciences partnered with Quest Diagnostics to facilitate sample collection through 7,000 patient sites nationwide. Targeted at adults aged 50 to 84 without recent cancer diagnoses, Cancerguard can be used annually with several payment plan options to improve accessibility. This launch marks a notable expansion of early detection tools in oncology.